Anti-glomerular basement membrane disease-treatment standard

Area of Science:

• Nephrology
• Immunology
• Rheumatology

Background:

• Anti-glomerular basement membrane (anti-GBM) disease is a rare small vessel vasculitis.
• It involves autoantibodies against type IV collagen, targeting glomerular and pulmonary capillaries.
• This leads to rapidly progressive glomerulonephritis and potentially pulmonary hemorrhage.

Purpose of the Study:

• To review current anti-GBM disease treatment standards.
• To discuss novel developments in pathophysiology, diagnosis, and management.
• To highlight areas for future research and treatment individualization.

Main Methods:

• Review of current literature on anti-GBM disease.
• Analysis of diagnostic criteria including clinical features, kidney biopsy, and antibody detection.
• Evaluation of established and emerging treatment modalities.

Main Results:

• Diagnosis relies on clinical presentation, linear IgG deposition on kidney biopsy, and/or circulating anti-GBM antibodies.
• Plasma exchange with cyclophosphamide and glucocorticoids has improved outcomes, especially for non-dialysis-dependent patients.
• Relapses are rare in classic anti-GBM disease, but 'double positive' (anti-GBM and ANCA) patients have higher relapse risk.

Conclusions:

• Treatment decisions for dialysis-dependent patients require careful consideration of biopsy findings and clinical severity.
• Long-term maintenance immunosuppression is not standard for classic anti-GBM disease but is needed for 'double positive' patients.
• Future research should focus on optimizing cyclophosphamide use, rituximab's role, and novel therapies like imlifidase for improved patient outcomes.